07 March 2024
07 March 2024
Despite declines in sales and EPS, Merck recorded a stable dividend of €2.20 per share for both 2023 and the preceding year.
NICE will not endorse Enhertu for NHS use without a commercial arrangement that leads to a cost-effective price.
The challenges and opportunities surrounding Africa becoming a clinical trials global force were discussed on day one of CTS Europe.
The agreement outlines the potential for Merus to earn up to $1.5bn payments from Gilead.
J&J submitted a new application to the EMA for the approval of its Darzalex combination therapy for multiple myeloma.
The company will use the funding proceeds to conduct Phase II and III clinical trials of its lead candidate, ESK-001.
Lilly witnessed the largest market capitalisation growth of 59.2% to $553.4bn in 2023, displacing Johnson & Johnson as the top player in the biopharmaceutical industry.
Avacta Group has filed a patent for therapeutic conjugates with extended circulating serum half-life, linked through a FAPa-cleavable linker.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
